Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.85
-0.2100-10.19%
Pre-market: 1.930.0760+4.11%06:19 EDT
Volume:1.60M
Turnover:3.09M
Market Cap:41.93M
PE:-0.14
High:2.07
Open:2.02
Low:1.84
Close:2.06
52wk High:10.99
52wk Low:1.79
Shares:22.66M
Float Shares:17.07M
Volume Ratio:1.38
T/O Rate:9.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.13
PE(LYR):-0.10

Loading ...

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
14 hours ago

Karyopharm Grants 1,850 Inducement RSUs to Two New Hires

Reuters
·
14 hours ago

Karyopharm submits sNDA to FDA for XPOVIO

TIPRANKS
·
Aug 31

Karyopharm Seeks FDA Accelerated Approval for Xpovio-Ruxolitinib Combo in Myelofibrosis

Reuters
·
Aug 31

Karyopharm Submits Supplemental New Drug Application to the FDA for Xpovio® (Selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

THOMSON REUTERS
·
Aug 31

Karyopharm Therapeutics - Expects FDA Decision on Snda Filing Acceptance in Q4 2026

THOMSON REUTERS
·
Aug 31

Karyopharm Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Karyopharm Q2 Revenue Falls as License Revenue Drops; Expects Funds to Last into September

Reuters
·
Aug 13

Karyopharm Q2 FY26 Net Loss Widens to $67 Million; Revenue Falls 11.85% to $33.4 Million

Reuters
·
Aug 13

Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate

Benzinga Earnings
·
Aug 13

Karyopharm Therapeutics Q2 Net Income USD -67.023 Million

Reuters
·
Aug 13

Karyopharm Therapeutics Q2 Operating Expenses USD 55.958 Million

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics - Actively Evaluating Financing Opportunities and Strategic Alternatives with Centerview Partners

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics - Expects Existing Liquidity to Fund Operations into September 2026

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics - Planned August Snda Submission for Selinexor Plus Ruxolitinib in Myelofibrosis Remains on Track

THOMSON REUTERS
·
Aug 13

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis Snda Submission

THOMSON REUTERS
·
Aug 13

Karyopharm Therapeutics Inc. Expected to Post a Loss of $1.28 a Share - Earnings Preview

Reuters
·
Aug 11

Karyopharm to Report Q2 2026 Results, Host Conference Call

Reuters
·
Aug 10

Karyopharm Therapeutics Inc. Expected to Post a Loss of $1.28 a Share - Earnings Preview

Reuters
·
Aug 08

Karyopharm Grants 333 RSUs to Newly Hired Employee Under Inducement Plan

Reuters
·
Aug 04